GH Research PLC (GHRS)

11.03 -0.16 (-1.43%) At close: 04:00PM EDT

GH Research PLC

Joshua Dawson House
Dawson Street
Dublin D02 RY95
Ireland
353 1 437 8334
https://www.ghres.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 49

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Florian Schonharting M.Sc. (Econ)	Co-Founder & Non-Executive Chairman of the Board	N/A	N/A	1969
Dr. Theis Terwey M.D.	Co-Founder & CEO	N/A	N/A	1976
Mr. Magnus Halle	Co-Founder & MD of Ireland	N/A	N/A	1997
Ms. Julie Ryan F.C.A.	Vice President of Finance	N/A	N/A	1986
Mr. Aaron Cameron M.B.A.	Chief Operating Officer	N/A	N/A	1985
Mr. Naoise Gaffney	VP & Head of Intellectual Property	N/A	N/A	N/A
Dr. Velichka Valcheva M.D.	Chief Medical Officer	N/A	N/A	1975

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Corporate governance

GH Research PLC’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.